These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 17254822)

  • 1. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T; Padilla A
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B; Arrabal S
    Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A; Ironside JW; Giangrande P
    Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
    Ironside JW; Head MW
    Haemophilia; 2004 Oct; 10 Suppl 4():64-9. PubMed ID: 15479374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
    Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
    Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease.
    Cervia JS; Sowemimo-Coker SO; Ortolano GA; Wilkins K; Schaffer J; Wortham ST
    Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
    Ludlam CA; Turner ML
    Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of accidental transmission of transmissible spongiform encephalopathy: identification of emerging issues.
    Ramasamy I
    Public Health; 2004 Sep; 118(6):409-20. PubMed ID: 15313594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
    Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
    Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prions and orthopedic surgery.
    Doerr HW; Cinatl J; Stürmer M; Rabenau HF
    Infection; 2003 Jun; 31(3):163-71. PubMed ID: 12789474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The risk of variant Creutzfeldt-Jakob disease in the Netherlands and the effect of preventive measures].
    Kersseboom R; Koekoek SC; Richardus JH
    Ned Tijdschr Geneeskd; 2002 Apr; 146(16):754-9. PubMed ID: 11998352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance of prions during plasma protein manufacture.
    Burdick MD; Pifat DY; Petteway SR; Cai K
    Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion transmission of human prion diseases.
    Zou S; Fang CT; Schonberger LB
    Transfus Med Rev; 2008 Jan; 22(1):58-69. PubMed ID: 18063192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies.
    Beisel CE; Morens DM
    Clin Infect Dis; 2004 Mar; 38(5):697-704. PubMed ID: 14986255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transmissible spongiform encephalopathies--illnesses in the human].
    Budka H
    Wien Med Wochenschr; 1998; 148(4):86-95. PubMed ID: 9611348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy.
    Brown P
    Haemophilia; 2007 Dec; 13 Suppl 5():33-40. PubMed ID: 18078395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of spiking materials for studies on the clearance of agents of transmissible spongiform encephalopathy during plasma fractionation.
    Foster PR
    Biologicals; 2008 Mar; 36(2):142-3. PubMed ID: 17400473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partitioning of TSE infectivity during ethanol fractionation of human plasma.
    Gregori L; Maring JA; MacAuley C; Dunston B; Rentsch M; Kempf C; Rohwer RG
    Biologicals; 2004 Mar; 32(1):1-10. PubMed ID: 15026020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.